Semler Scientific (SMLR) Financials

$44.32 -0.61 (-1.36%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$43.92 -0.40 (-0.89%)

As of 05/23/2025 07:59 PM Eastern

Annual Income Statements for Semler Scientific

This table shows Semler Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	41	21	14
Consolidated Net Income / (Loss)	41	21	14
Net Income / (Loss) Continuing Operations	41	21	14
Total Pre-Tax Income	48	24	18
Total Operating Income	21	22	17
Total Gross Profit	52	61	52
Total Revenue	56	68	57
Operating Revenue	56	68	57
Total Cost of Revenue	4.76	6.98	4.25
Operating Cost of Revenue	4.76	6.98	4.25
Total Operating Expenses	31	39	35
Selling, General & Admin Expense	13	14	13
Marketing Expense	13	18	18
Research & Development Expense	4.79	5.77	4.81
Restructuring Charge	0.00	0.73	0.00
Total Other Income / (Expense), net	27	1.84	0.49
Interest & Investment Income	1.88	2.47	0.49
Other Income / (Expense), net	25	-0.63	-0.01
Income Tax Expense	6.99	3.52	3.37
Basic Earnings per Share	$5.66	$3.06	$2.13
Weighted Average Basic Shares Outstanding	7.23M	6.73M	6.73M
Diluted Earnings per Share	$5.13	$2.63	$1.79
Weighted Average Diluted Shares Outstanding	7.98M	7.82M	8.00M
Weighted Average Basic & Diluted Shares Outstanding	9.60M	7.03M	6.84M

This table shows Semler Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	29	5.61	0.01	6.07	4.22	5.51	5.88	4.97	3.22	3.68
Consolidated Net Income / (Loss)	29	5.61	0.01	6.07	4.22	5.51	5.88	4.97	3.22	3.68
Net Income / (Loss) Continuing Operations	29	5.61	0.01	6.07	4.22	5.51	5.88	4.97	3.22	3.68
Total Pre-Tax Income	33	6.38	1.14	7.80	2.81	6.99	7.67	6.63	3.96	4.60
Total Operating Income	3.54	5.07	5.35	6.98	2.52	6.30	7.18	6.26	3.62	4.47
Total Gross Profit	11	12	13	15	12	15	17	17	13	13
Total Revenue	12	14	14	16	15	16	19	18	14	14
Operating Revenue	12	14	14	16	15	16	19	18	14	14
Total Cost of Revenue	1.10	1.16	1.26	1.25	3.39	1.11	1.22	1.27	1.18	1.14
Operating Cost of Revenue	1.10	1.16	1.26	1.25	3.39	1.11	1.22	1.27	1.18	1.14
Total Operating Expenses	7.77	7.29	7.86	7.68	9.15	8.91	10	11	9.00	8.44
Selling, General & Admin Expense	3.77	3.13	2.96	2.87	3.26	3.71	3.46	3.86	2.98	3.05
Marketing Expense	2.97	2.98	3.46	3.68	4.55	3.42	4.99	5.19	4.66	4.15
Research & Development Expense	1.03	1.19	1.44	1.14	1.21	1.17	1.76	1.63	1.37	1.24
Total Other Income / (Expense), net	29	1.31	-4.21	0.82	0.29	0.69	0.49	0.38	0.34	0.13
Interest & Investment Income	0.18	0.17	0.71	0.82	0.70	0.69	0.60	0.48	-	-
Other Income / (Expense), net	29	1.14	-4.93	0.00	-0.41	-0.00	-0.11	-0.11	-0.00	-0.00
Income Tax Expense	3.37	0.77	1.13	1.72	-1.41	1.47	1.79	1.66	0.74	0.93
Basic Earnings per Share	$3.98	$0.80	$0.00	$0.88	$0.62	$0.82	$0.88	$0.74	$0.48	$0.55
Weighted Average Basic Shares Outstanding	7.23M	7.05M	6.94M	6.89M	6.73M	6.72M	6.71M	6.70M	6.73M	6.68M
Diluted Earnings per Share	$3.63	$0.72	$0.00	$0.78	$0.54	$0.71	$0.75	$0.63	$0.41	$0.46
Weighted Average Diluted Shares Outstanding	7.98M	7.77M	7.80M	7.78M	7.82M	7.82M	7.87M	7.90M	8.00M	7.94M
Weighted Average Basic & Diluted Shares Outstanding	9.60M	7.27M	7.13M	7.07M	7.03M	6.87M	6.86M	6.85M	6.84M	6.84M

This table details how cash moves in and out of Semler Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-48	34	-14
Net Cash From Operating Activities	24	21	17
Net Cash From Continuing Operating Activities	24	21	17
Net Income / (Loss) Continuing Operations	41	21	14
Consolidated Net Income / (Loss)	41	21	14
Depreciation Expense	0.58	0.60	0.59
Non-Cash Adjustments To Reconcile Net Income	-24	4.55	1.23
Changes in Operating Assets and Liabilities, net	6.92	-4.40	1.32
Net Cash From Investing Activities	-190	18	-27
Net Cash From Continuing Investing Activities	-190	18	-27
Purchase of Property, Plant & Equipment	-0.05	-0.35	-2.16
Purchase of Investments	-0.50	-59	-20
Sale and/or Maturity of Investments	0.00	78	-4.68
Other Investing Activities, net	-189	-0.48	0.00
Net Cash From Financing Activities	117	-5.41	-4.94
Net Cash From Continuing Financing Activities	117	-5.41	-4.94
Repurchase of Common Equity	-3.00	-1.95	-4.99
Issuance of Common Equity	120	0.00	-
Other Financing Activities, net	0.59	-3.46	0.05
Cash Income Taxes Paid	2.26	4.06	2.40

This table details how cash moves in and out of Semler Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	2.25	-0.76	-55	5.55	20	-2.00	34	-18	-23	5.51
Net Cash From Operating Activities	7.43	6.43	4.93	5.62	4.44	4.83	11	0.86	1.71	8.02
Net Cash From Continuing Operating Activities	7.43	6.43	4.93	5.62	4.44	4.83	11	0.86	1.71	8.02
Net Income / (Loss) Continuing Operations	29	5.61	0.01	6.07	4.22	5.51	5.88	4.97	3.22	3.68
Consolidated Net Income / (Loss)	29	5.61	0.01	6.07	4.22	5.51	5.88	4.97	3.22	3.68
Depreciation Expense	0.10	0.13	0.17	0.18	0.16	0.16	0.15	0.13	0.13	0.15
Non-Cash Adjustments To Reconcile Net Income	-29	-0.91	5.34	0.16	3.00	0.50	0.42	0.63	0.17	0.14
Changes in Operating Assets and Liabilities, net	6.70	1.59	-0.58	-0.79	-2.94	-1.34	4.75	-4.87	-1.80	4.06
Net Cash From Investing Activities	-121	-8.44	-60	-0.08	19	-6.78	25	-18	-24	-0.49
Net Cash From Continuing Investing Activities	-121	-8.44	-60	-0.08	19	-6.78	25	-18	-24	-0.49
Purchase of Property, Plant & Equipment	0.03	-0.04	0.03	-0.08	0.74	-0.15	-0.30	-0.64	-0.81	-0.49
Other Investing Activities, net	-121	-8.40	-	-	-0.48	-	-	-	-	-
Net Cash From Financing Activities	116	1.25	0.11	0.01	-3.24	-0.05	-1.98	-0.15	0.08	-2.03
Net Cash From Continuing Financing Activities	116	1.25	0.11	0.01	-3.24	-0.05	-1.98	-0.15	0.08	-2.03
Repurchase of Common Equity	-2.41	-0.49	-	-	-	-	-	-	-	-2.05
Issuance of Common Equity	117	-	-	-	-	-	-	-	-	-
Other Financing Activities, net	1.17	-0.80	0.21	0.01	-3.24	-0.05	-0.03	-0.15	0.08	0.02

This table presents Semler Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	240	78	63
Total Current Assets	23	66	49
Cash & Equivalents	8.82	57	23
Restricted Cash	0.13	0.13	0.00
Note & Lease Receivable	6.10	0.00	-
Accounts Receivable	4.38	6.13	3.88
Inventories, net	0.36	0.45	0.47
Prepaid Expenses	2.90	2.04	1.47
Plant, Property, & Equipment, net	1.91	3.01	2.48
Total Noncurrent Assets	215	9.12	11
Long-Term Investments	0.51	0.51	0.82
Noncurrent Note & Lease Receivables	0.00	5.37	4.68
Intangible Assets	215	0.00	-
Noncurrent Deferred & Refundable Income Taxes	0.00	2.96	2.30
Other Noncurrent Operating Assets	0.09	0.27	3.51
Total Liabilities & Shareholders' Equity	240	78	63
Total Liabilities	9.08	6.27	7.02
Total Current Liabilities	6.31	6.20	6.86
Accounts Payable	0.14	0.40	0.84
Accrued Expenses	5.17	4.50	4.75
Current Deferred Revenue	0.77	1.12	1.16
Other Current Liabilities	0.23	0.18	0.11
Total Noncurrent Liabilities	2.77	0.07	0.16
Noncurrent Deferred & Payable Income Tax Liabilities	2.77	0.00	-
Other Noncurrent Operating Liabilities	0.00	0.07	0.16
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	231	72	56
Total Preferred & Common Equity	231	72	56
Total Common Equity	231	72	56
Common Stock	130	12	16
Retained Earnings	101	60	39

This table presents Semler Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	92	85	84	79	75	70	61
Total Current Assets	21	24	72	64	61	56	52
Cash & Equivalents	6.57	7.33	63	37	39	5.31	46
Restricted Cash	0.13	0.13	0.13	-	-	-	-
Note & Lease Receivable	6.10	6.10	-	-	-	-	-
Accounts Receivable	6.67	7.47	6.13	5.97	6.03	9.34	3.67
Inventories, net	0.38	0.39	0.41	0.44	0.48	0.51	0.51
Prepaid Expenses	1.65	2.27	2.48	1.95	2.42	2.77	1.96
Plant, Property, & Equipment, net	1.74	2.39	0.00	3.26	3.69	3.58	2.62
Total Noncurrent Assets	69	59	11	12	11	11	6.62
Long-Term Investments	0.51	0.51	0.51	0.82	0.82	0.82	0.82
Noncurrent Note & Lease Receivables	0.00	0.00	7.44	5.46	4.96	5.07	1.18
Intangible Assets	64	55	-	-	-	-	-
Noncurrent Deferred & Refundable Income Taxes	3.32	3.12	3.10	2.78	2.51	2.38	2.35
Other Noncurrent Operating Assets	0.65	0.13	0.25	2.74	2.74	2.82	2.27
Total Liabilities & Shareholders' Equity	92	85	84	79	75	70	61
Total Liabilities	6.84	6.39	5.95	8.67	10	9.06	8.57
Total Current Liabilities	6.84	6.36	5.90	8.58	10	8.92	8.39
Accounts Payable	0.55	0.23	0.41	0.30	0.51	0.30	0.48
Accrued Expenses	5.26	5.09	4.31	7.00	8.24	7.21	6.65
Current Deferred Revenue	0.81	0.84	1.00	1.12	1.19	1.29	1.16
Other Current Liabilities	0.23	0.21	0.19	0.16	0.14	0.13	0.09
Total Noncurrent Liabilities	0.00	0.02	0.05	0.09	0.12	0.14	0.18
Other Noncurrent Operating Liabilities	0.00	0.02	0.05	0.09	0.12	0.14	0.18
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	85	78	78	71	65	61	52
Total Preferred & Common Equity	85	78	78	71	65	61	52
Total Common Equity	85	78	78	71	65	61	52
Common Stock	14	13	12	15	15	17	16
Retained Earnings	71	66	66	56	50	44	36

This table displays calculated financial ratios and metrics derived from Semler Scientific's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-17.44%	20.28%	6.90%
EBITDA Growth	109.58%	24.97%	-11.39%
EBIT Growth	112.71%	25.76%	-11.56%
NOPAT Growth	-5.94%	36.46%	-19.08%
Net Income Growth	98.70%	43.69%	-16.82%
EPS Growth	95.06%	46.93%	-15.57%
Operating Cash Flow Growth	14.44%	22.14%	8.76%
Free Cash Flow Firm Growth	-1,226.03%	75.92%	-33.92%
Invested Capital Growth	1,486.17%	18.55%	58.96%
Revenue Q/Q Growth	-4.48%	1.89%	4.14%
EBITDA Q/Q Growth	184.70%	-6.19%	11.81%
EBIT Q/Q Growth	192.61%	-6.48%	12.49%
NOPAT Q/Q Growth	2.25%	4.96%	11.45%
Net Income Q/Q Growth	157.00%	5.13%	13.55%
EPS Q/Q Growth	151.47%	5.20%	14.74%
Operating Cash Flow Q/Q Growth	13.93%	14.69%	0.30%
Free Cash Flow Firm Q/Q Growth	-305.42%	65.28%	-30.53%
Invested Capital Q/Q Growth	183.18%	0.19%	96.30%
Profitability Metrics	-	-	-
Gross Margin	91.55%	89.76%	92.50%
EBITDA Margin	82.75%	32.60%	31.38%
Operating Margin	37.19%	32.64%	30.35%
EBIT Margin	81.73%	31.72%	30.34%
Profit (Net Income) Margin	72.65%	30.19%	25.27%
Tax Burden Percent	85.41%	85.41%	80.97%
Interest Burden Percent	104.08%	111.42%	102.87%
Effective Tax Rate	14.59%	14.59%	19.03%
Return on Invested Capital (ROIC)	15.20%	147.81%	145.31%
ROIC Less NNEP Spread (ROIC-NNEP)	-53.20%	144.72%	144.35%
Return on Net Nonoperating Assets (RNNOA)	11.84%	-115.52%	-117.01%
Return on Equity (ROE)	27.04%	32.29%	28.30%
Cash Return on Invested Capital (CROIC)	-161.08%	130.84%	99.78%
Operating Return on Assets (OROA)	28.95%	30.73%	30.34%
Return on Assets (ROA)	25.73%	29.25%	25.27%
Return on Common Equity (ROCE)	27.04%	32.29%	28.30%
Return on Equity Simple (ROE_SIMPLE)	17.72%	28.67%	25.73%
Net Operating Profit after Tax (NOPAT)	18	19	14
NOPAT Margin	31.76%	27.88%	24.57%
Net Nonoperating Expense Percent (NNEP)	68.40%	3.10%	0.97%
Return On Investment Capital (ROIC_SIMPLE)	7.75%	26.48%	-
Cost of Revenue to Revenue	8.45%	10.24%	7.50%
SG&A Expenses to Revenue	22.62%	20.96%	22.47%
R&D to Revenue	8.51%	8.47%	8.48%
Operating Expenses to Revenue	54.36%	57.12%	62.15%
Earnings before Interest and Taxes (EBIT)	46	22	17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	47	22	18
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.70	4.24	4.05
Price to Tangible Book Value (P/TBV)	24.35	4.24	4.05
Price to Revenue (P/Rev)	6.97	4.46	3.98
Price to Earnings (P/E)	9.59	14.79	15.76
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	10.42%	6.76%	6.35%
Enterprise Value to Invested Capital (EV/IC)	1.73	17.67	15.45
Enterprise Value to Revenue (EV/Rev)	6.80	3.62	3.21
Enterprise Value to EBITDA (EV/EBITDA)	8.22	11.09	10.22
Enterprise Value to EBIT (EV/EBIT)	8.32	11.40	10.57
Enterprise Value to NOPAT (EV/NOPAT)	21.42	12.97	13.05
Enterprise Value to Operating Cash Flow (EV/OCF)	15.69	11.56	10.41
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	14.65	19.01
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.22	-0.80	-0.81
Leverage Ratio	1.05	1.10	1.12
Compound Leverage Factor	1.09	1.23	1.15
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	27.47	32.91	22.79
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.59	10.64	7.13
Quick Ratio	3.06	10.21	6.85
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-189	17	9.56
Operating Cash Flow to CapEx	47,862.75%	6,182.61%	808.47%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.35	0.97	1.00
Accounts Receivable Turnover	10.72	13.62	15.11
Inventory Turnover	11.85	15.28	8.35
Fixed Asset Turnover	22.91	24.87	25.11
Accounts Payable Turnover	17.56	11.29	6.65
Days Sales Outstanding (DSO)	34.05	26.79	24.16
Days Inventory Outstanding (DIO)	30.79	23.88	43.74
Days Payable Outstanding (DPO)	20.78	32.32	54.85
Cash Conversion Cycle (CCC)	44.06	18.35	13.04
Capital & Investment Metrics	-	-	-
Invested Capital	221	14	12
Invested Capital Turnover	0.48	5.30	5.91
Increase / (Decrease) in Invested Capital	207	2.18	4.37
Enterprise Value (EV)	383	247	182
Market Capitalization	392	304	226
Book Value per Share	$31.76	$10.45	$8.14
Tangible Book Value per Share	$2.22	$10.45	$8.14
Total Capital	231	72	56
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-9.46	-58	-44
Capital Expenditures (CapEx)	0.05	0.35	2.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	7.42	2.41	-1.04
Debt-free Net Working Capital (DFNWC)	16	60	42
Net Working Capital (NWC)	16	60	42
Net Nonoperating Expense (NNE)	-23	-1.57	-0.40
Net Nonoperating Obligations (NNO)	-9.46	-58	-44
Total Depreciation and Amortization (D&A)	0.58	0.60	0.59
Debt-free, Cash-free Net Working Capital to Revenue	13.19%	3.54%	-1.83%
Debt-free Net Working Capital to Revenue	29.09%	87.62%	74.18%
Net Working Capital to Revenue	29.09%	87.62%	74.18%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$5.66	$3.06	$2.13
Adjusted Weighted Average Basic Shares Outstanding	7.23M	6.73M	6.73M
Adjusted Diluted Earnings per Share	$5.13	$2.63	$1.79
Adjusted Weighted Average Diluted Shares Outstanding	7.98M	7.82M	8.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	9.60M	7.03M	6.84M
Normalized Net Operating Profit after Tax (NOPAT)	18	20	14
Normalized NOPAT Margin	31.76%	28.80%	24.57%
Pre Tax Income Margin	85.06%	35.35%	31.21%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	7.34%	9.47%	34.84%

This table displays calculated financial ratios and metrics derived from Semler Scientific's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-17.55%	-17.19%	-22.25%	-12.65%	9.15%	16.15%	25.47%	29.89%	19.52%	0.40%
EBITDA Growth	1,328.48%	-1.78%	-91.79%	13.95%	-39.19%	39.83%	35.39%	53.23%	100.91%	-14.72%
EBIT Growth	1,431.87%	-1.41%	-94.02%	13.48%	-41.48%	41.04%	36.52%	55.99%	112.09%	-15.04%
NOPAT Growth	-16.05%	-10.34%	-99.06%	15.94%	28.72%	39.30%	35.50%	39.52%	94.56%	-13.96%
Net Income Growth	591.92%	1.72%	-99.81%	22.22%	31.25%	50.04%	44.31%	47.89%	113.40%	-11.45%
EPS Growth	572.22%	1.41%	-100.00%	23.81%	31.71%	54.35%	47.06%	53.66%	127.78%	-9.80%
Operating Cash Flow Growth	67.20%	33.00%	-55.93%	553.19%	159.77%	-39.77%	79.71%	-42.68%	3.20%	5.03%
Free Cash Flow Firm Growth	-12,861.20%	-1,919.17%	-2,233.25%	448.26%	212.18%	-161.20%	-42.66%	-146.49%	-16.00%	125.79%
Invested Capital Growth	1,486.17%	461.16%	458.15%	-20.41%	18.55%	132.28%	28.51%	71.63%	58.96%	-17.46%
Revenue Q/Q Growth	-8.13%	-6.59%	-9.04%	5.62%	-7.72%	-12.30%	2.19%	31.98%	-1.79%	-5.27%
EBITDA Q/Q Growth	412.51%	969.31%	-91.71%	214.46%	-64.76%	-10.57%	14.99%	67.82%	-18.97%	-13.41%
EBIT Q/Q Growth	421.98%	1,367.38%	-93.94%	229.93%	-66.41%	-10.94%	14.96%	70.14%	-19.04%	-13.79%
NOPAT Q/Q Growth	-28.74%	8,509.91%	-99.05%	43.64%	-23.89%	-9.73%	17.49%	59.47%	-17.63%	-12.20%
Net Income Q/Q Growth	420.70%	50,890.91%	-99.82%	43.88%	-23.45%	-6.21%	18.31%	54.51%	-12.49%	-9.79%
EPS Q/Q Growth	404.17%	0.00%	-100.00%	44.44%	-23.94%	-5.33%	19.05%	53.66%	-10.87%	-9.80%
Operating Cash Flow Q/Q Growth	15.60%	30.22%	-12.27%	26.61%	-8.05%	-56.85%	1,200.35%	-49.65%	-78.68%	28.75%
Free Cash Flow Firm Q/Q Growth	-241.63%	-3.48%	-742.66%	461.71%	154.05%	-209.32%	204.92%	-80.94%	-129.49%	2.42%
Invested Capital Q/Q Growth	183.18%	10.96%	408.13%	-0.66%	0.19%	10.37%	-27.54%	47.96%	96.30%	-38.94%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	91.13%	91.44%	91.32%	92.16%	77.52%	93.19%	93.45%	93.03%	91.44%	91.90%
EBITDA Margin	261.79%	46.93%	4.10%	44.99%	15.11%	39.57%	38.80%	34.48%	27.12%	32.87%
Operating Margin	28.53%	37.49%	36.99%	43.87%	16.74%	38.61%	38.59%	34.36%	26.21%	31.80%
EBIT Margin	260.99%	45.94%	2.92%	43.88%	14.05%	38.59%	38.00%	33.77%	26.20%	31.78%
Profit (Net Income) Margin	235.27%	41.51%	0.08%	38.19%	28.03%	33.80%	31.60%	27.29%	23.31%	26.16%
Tax Burden Percent	89.66%	87.98%	0.97%	77.89%	150.05%	78.91%	76.69%	74.91%	81.27%	79.87%
Interest Burden Percent	100.54%	102.71%	268.79%	111.74%	133.00%	110.99%	108.45%	107.87%	109.49%	103.07%
Effective Tax Rate	10.34%	12.02%	99.03%	22.11%	-50.05%	21.09%	23.31%	25.09%	18.73%	20.13%
Return on Invested Capital (ROIC)	12.24%	42.23%	0.53%	143.96%	133.21%	204.68%	170.58%	113.73%	125.98%	208.57%
ROIC Less NNEP Spread (ROIC-NNEP)	-65.10%	38.63%	0.67%	142.78%	132.35%	203.63%	169.78%	113.05%	125.31%	208.31%
Return on Net Nonoperating Assets (RNNOA)	14.48%	-15.85%	-0.28%	-110.68%	-105.65%	-170.68%	-136.93%	-84.88%	-101.58%	-179.65%
Return on Equity (ROE)	26.73%	26.38%	0.25%	33.28%	27.56%	34.00%	33.65%	28.85%	24.41%	28.92%
Cash Return on Invested Capital (CROIC)	-161.08%	-101.52%	-96.22%	148.87%	130.84%	102.21%	123.93%	57.99%	99.78%	207.67%
Operating Return on Assets (OROA)	92.43%	31.55%	2.25%	37.51%	13.61%	36.80%	36.91%	32.72%	26.20%	30.92%
Return on Assets (ROA)	83.32%	28.51%	0.06%	32.65%	27.16%	32.23%	30.70%	26.44%	23.31%	25.45%
Return on Common Equity (ROCE)	26.73%	26.38%	0.25%	33.28%	27.56%	34.00%	33.65%	28.85%	24.41%	28.92%
Return on Equity Simple (ROE_SIMPLE)	0.00%	18.64%	20.18%	27.84%	0.00%	27.66%	27.18%	26.04%	0.00%	24.10%
Net Operating Profit after Tax (NOPAT)	3.18	4.46	0.05	5.43	3.78	4.97	5.51	4.69	2.94	3.57
NOPAT Margin	25.58%	32.98%	0.36%	34.17%	25.12%	30.46%	29.60%	25.74%	21.30%	25.40%
Net Nonoperating Expense Percent (NNEP)	77.35%	3.60%	-0.13%	1.19%	0.86%	1.05%	0.80%	0.68%	0.68%	0.26%
Return On Investment Capital (ROIC_SIMPLE)	1.38%	-	-	-	5.27%	-	-	-	-	-
Cost of Revenue to Revenue	8.87%	8.56%	8.68%	7.84%	22.48%	6.81%	6.55%	6.97%	8.56%	8.10%
SG&A Expenses to Revenue	30.39%	23.16%	20.49%	18.03%	21.66%	22.74%	18.59%	21.20%	21.59%	21.68%
R&D to Revenue	8.28%	8.78%	9.96%	7.16%	8.02%	7.20%	9.47%	8.95%	9.89%	8.86%
Operating Expenses to Revenue	62.60%	53.96%	54.34%	48.29%	60.78%	54.58%	54.86%	58.67%	65.23%	60.10%
Earnings before Interest and Taxes (EBIT)	32	6.21	0.42	6.98	2.12	6.30	7.07	6.15	3.61	4.46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	32	6.34	0.59	7.15	2.28	6.46	7.22	6.28	3.74	4.62
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.70	1.97	3.10	2.64	4.24	2.46	2.75	3.00	4.05	4.88
Price to Tangible Book Value (P/TBV)	24.35	8.05	10.36	2.64	4.24	2.46	2.75	3.00	4.05	4.88
Price to Revenue (P/Rev)	6.97	2.85	3.94	3.12	4.46	2.60	2.78	3.01	3.98	4.69
Price to Earnings (P/E)	9.59	10.56	15.37	9.47	14.79	8.88	10.13	11.51	15.76	20.24
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	10.42%	9.47%	6.51%	10.56%	6.76%	11.26%	9.87%	8.69%	6.35%	4.94%
Enterprise Value to Invested Capital (EV/IC)	1.73	2.06	3.34	10.24	17.67	8.41	10.08	8.02	15.45	34.86
Enterprise Value to Revenue (EV/Rev)	6.80	2.73	3.81	2.16	3.62	1.75	1.97	2.29	3.21	3.84
Enterprise Value to EBITDA (EV/EBITDA)	8.22	9.83	14.27	6.15	11.09	4.94	5.82	6.99	10.22	13.14
Enterprise Value to EBIT (EV/EBIT)	8.32	10.23	14.87	6.32	11.40	5.06	5.97	7.20	10.57	13.67
Enterprise Value to NOPAT (EV/NOPAT)	21.42	9.20	13.17	7.20	12.97	6.47	7.61	9.15	13.05	16.72
Enterprise Value to Operating Cash Flow (EV/OCF)	15.69	7.50	11.85	5.44	11.56	6.30	5.84	8.30	10.41	12.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	6.10	14.65	11.50	9.15	17.48	19.01	15.18
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.22	-0.41	-0.42	-0.78	-0.80	-0.84	-0.81	-0.75	-0.81	-0.86
Leverage Ratio	1.05	1.10	1.12	1.11	1.10	1.14	1.15	1.14	1.12	1.16
Compound Leverage Factor	1.06	1.13	3.00	1.24	1.47	1.27	1.25	1.23	1.23	1.20
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	27.28	16.88	24.91	23.82	32.08	14.96	13.48	14.99	22.08	20.70
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.59	3.14	3.72	12.18	10.64	7.51	6.03	6.23	7.13	6.16
Quick Ratio	3.06	2.83	3.28	11.67	10.21	7.23	5.74	5.87	6.85	5.87
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-204	-60	-58	8.99	1.60	-2.96	2.71	-2.58	-1.43	4.84
Operating Cash Flow to CapEx	0.00%	18,357.14%	0.00%	6,943.21%	0.00%	3,242.28%	3,795.25%	134.74%	210.85%	1,633.60%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.35	0.69	0.77	0.86	0.97	0.95	0.97	0.97	1.00	0.97
Accounts Receivable Turnover	10.72	9.33	9.15	8.51	13.62	13.89	11.17	8.25	15.11	14.24
Inventory Turnover	11.85	17.20	16.26	15.13	15.28	10.06	9.61	8.22	8.35	4.56
Fixed Asset Turnover	22.91	23.57	20.33	0.00	24.87	22.75	23.50	21.59	25.11	36.20
Accounts Payable Turnover	17.56	16.67	19.02	19.67	11.29	12.21	9.89	13.52	6.65	11.85
Days Sales Outstanding (DSO)	34.05	39.12	39.91	42.87	26.79	26.29	32.68	44.25	24.16	25.63
Days Inventory Outstanding (DIO)	30.79	21.22	22.45	24.12	23.88	36.27	37.97	44.39	43.74	80.13
Days Payable Outstanding (DPO)	20.78	21.90	19.19	18.56	32.32	29.89	36.90	26.99	54.85	30.81
Cash Conversion Cycle (CCC)	44.06	38.44	43.17	48.43	18.35	32.66	33.74	61.65	13.04	74.95
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	221	78	70	14	14	14	13	17	12	6.00
Invested Capital Turnover	0.48	1.28	1.49	4.21	5.30	6.72	5.76	4.42	5.91	8.21
Increase / (Decrease) in Invested Capital	207	64	58	-3.55	2.18	7.93	2.80	7.27	4.37	-1.27
Enterprise Value (EV)	383	161	235	142	247	117	127	140	182	209
Market Capitalization	392	168	243	205	304	174	180	183	226	255
Book Value per Share	$31.76	$11.96	$11.10	$11.08	$10.45	$10.32	$9.53	$8.94	$8.14	$7.70
Tangible Book Value per Share	$2.22	$2.93	$3.32	$11.08	$10.45	$10.32	$9.53	$8.94	$8.14	$7.70
Total Capital	231	85	78	78	72	71	65	61	56	52
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-9.46	-7.21	-7.98	-63	-58	-57	-53	-44	-44	-46
Capital Expenditures (CapEx)	-0.03	0.04	-0.03	0.08	-0.74	0.15	0.30	0.64	0.81	0.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)	7.42	7.95	9.86	3.12	2.41	-0.23	-1.16	3.71	-1.04	-2.24
Debt-free Net Working Capital (DFNWC)	16	15	17	66	60	56	51	47	42	43
Net Working Capital (NWC)	16	15	17	66	60	56	51	47	42	43
Net Nonoperating Expense (NNE)	-26	-1.15	0.04	-0.64	-0.44	-0.54	-0.37	-0.28	-0.28	-0.11
Net Nonoperating Obligations (NNO)	-9.46	-7.21	-7.98	-64	-58	-57	-53	-44	-44	-46
Total Depreciation and Amortization (D&A)	0.10	0.13	0.17	0.18	0.16	0.16	0.15	0.13	0.13	0.15
Debt-free, Cash-free Net Working Capital to Revenue	13.19%	13.50%	15.97%	4.73%	3.54%	-0.34%	-1.79%	6.09%	-1.83%	-4.12%
Debt-free Net Working Capital to Revenue	29.09%	24.87%	28.06%	100.18%	87.62%	83.38%	78.37%	76.67%	74.18%	79.54%
Net Working Capital to Revenue	29.09%	24.87%	28.06%	100.18%	87.62%	83.38%	78.37%	76.67%	74.18%	79.54%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.98	$0.80	$0.00	$0.88	$0.62	$0.82	$0.88	$0.74	$0.48	$0.55
Adjusted Weighted Average Basic Shares Outstanding	7.23M	7.05M	6.94M	6.89M	6.73M	6.72M	6.71M	6.70M	6.73M	6.68M
Adjusted Diluted Earnings per Share	$3.63	$0.72	$0.00	$0.78	$0.54	$0.71	$0.75	$0.63	$0.41	$0.46
Adjusted Weighted Average Diluted Shares Outstanding	7.98M	7.77M	7.80M	7.78M	7.82M	7.82M	7.87M	7.90M	8.00M	7.94M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	9.60M	7.27M	7.13M	7.07M	7.03M	6.87M	6.86M	6.85M	6.84M	6.84M
Normalized Net Operating Profit after Tax (NOPAT)	3.18	4.46	3.75	5.43	1.76	5.44	5.51	4.69	2.94	3.57
Normalized NOPAT Margin	25.58%	32.98%	25.89%	34.17%	11.72%	33.36%	29.60%	25.74%	21.30%	25.40%
Pre Tax Income Margin	262.41%	47.18%	7.86%	49.03%	18.68%	42.83%	41.20%	36.43%	28.68%	32.75%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	7.34%	3.69%	0.64%	0.00%	9.47%	9.96%	22.52%	0.00%	34.84%	39.56%

Frequently Asked Questions About Semler Scientific's Financials

When does Semler Scientific's financial year end?

According to the most recent income statement we have on file, Semler Scientific's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Semler Scientific's net income changed over the last 2 years?

Semler Scientific's net income appears to be on an upward trend, with a most recent value of $40.90 million in 2024, rising from $14.33 million in 2022. The previous period was $20.58 million in 2023. See where experts think Semler Scientific is headed by visiting Semler Scientific's forecast page.

What is Semler Scientific's operating income?

Semler Scientific's total operating income in 2024 was $20.93 million, based on the following breakdown:

Total Gross Profit: $51.54 million
Total Operating Expenses: $30.60 million

How has Semler Scientific revenue changed over the last 2 years?

Over the last 2 years, Semler Scientific's total revenue changed from $56.69 million in 2022 to $56.29 million in 2024, a change of -0.7%.

How much debt does Semler Scientific have?

Semler Scientific's total liabilities were at $9.08 million at the end of 2024, a 44.8% increase from 2023, and a 29.4% increase since 2022.

How much cash does Semler Scientific have?

In the past 2 years, Semler Scientific's cash and equivalents has ranged from $8.82 million in 2024 to $57.20 million in 2023, and is currently $8.82 million as of their latest financial filing in 2024.

How has Semler Scientific's book value per share changed over the last 2 years?

Over the last 2 years, Semler Scientific's book value per share changed from 8.14 in 2022 to 31.76 in 2024, a change of 290.1%.

Related Companies

This page (NASDAQ:SMLR) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Semler Scientific (SMLR) Financials

Frequently Asked Questions About Semler Scientific's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Semler Scientific (SMLR) Financials

Annual Income Statements for Semler Scientific

Quarterly Income Statements for Semler Scientific

Annual Cash Flow Statements for Semler Scientific

Quarterly Cash Flow Statements for Semler Scientific

Annual Balance Sheets for Semler Scientific

Quarterly Balance Sheets for Semler Scientific

Annual Metrics And Ratios for Semler Scientific

Quarterly Metrics And Ratios for Semler Scientific

Frequently Asked Questions About Semler Scientific's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools